undamentalytics Newsletter
Sign in

Agios Pharmaceuticals, Inc. balance sheet

At the end of fiscal 2025, Agios Pharmaceuticals, Inc. had total assets of $1.30bn, total liabilities of $104m and shareholders' equity of $1.19bn. It held $89.1m in cash against $0 of debt: net cash of $89.1m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents118917214721611037181127203139887689100
Receivables———2330——040————
Inventory——————017150819283336
Total current assets—1301703603375604456146126371,064833834966942718
Total assets—1372014924206196148588918531,4381,2399371,6631,2971,108
Accounts payable—3411151723182218171910171816
Deferred revenue (current)—252536203638331100—————
Total current liabilities—353761538895949394606368818270
Total debt0000000000000000
Total liabilities—————26123917125045314613812612210482
Shareholders' equity−53−721314243453593766886414001,2921,1018111,5411,1931,026
Net debt (negative = net cash)−118−91−72−14−72−161−103−71−81−127−203−139−88−76−89−100
Shares outstanding—4m—37m38m42m49m58m68m69m54m55m56m57m58m60m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: AGIO vs SEPNAGIO vs KYMRAGIO vs XNCRAGIO vs FDMT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Agios Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Agios Pharmaceuticals, Inc.